With $354,826 in CMTA funding, the SENSE Trial is an HSN1 clinical trial investigating a potential treatment for hereditary sensory neuropathy type 1, with active participation now complete and final data analysis underway.
Simply CMT
More From Simply CMT
-
When Is the Right Time to Begin Treatment in CMT1A and CMT1E?
What if the timing of treatment could change everything? CMTA is funding a new study to find the optimal window for treating CMT1A and CMT1E; and to discover how to tell if it's working.
-
